Last edition
News about "rare genetic disorders"
LEO Pharma has agreed to acquire worldwide rights to Tanabe Pharma’s oral MC1R agonist dersimelagon for up to USD 435 million in upfront and near-term milestones, strengthening its rare dermatology pipeline for EPP and XLP.
Rare Genetic Disorders | 19/08/2026 | By News Bureau
AskBio Doses First Participant in Phase 1/2 Trial for Pompe Disease Gene Therapy
AskBio has dosed the first participant in its Phase 1/2 PROGRESS-GT LOPD trial evaluating investigational gene therapy AB-1009 for late-onset Pompe disease, advancing research into potential long-term treatment solutions for the rare genetic disorder.
Rare Genetic Disorders | 14/05/2026 | By News Bureau
THX Pharma and Biocodex Sign Licensing Deal for Rare Disease Drug Candidates
Biocodex secures global rights to Batten-1 and North American rights to TX01 from THX Pharma in a deal worth up to Euro 173 million to advance treatments for juvenile Batten disease, Gaucher disease and Niemann-Pick type C.
Rare Genetic Disorders | 13/02/2026 | By News Bureau | 225
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy